Optimizing the erythromycin breath test for use in cancer patients

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3480-3485

  Rivory, L P ^a   Slaviero, K ^a   Seale, J P ^a   Hoskins, J M ^a   Boyer, M ^a   Beale, P J ^a   Millward, M J ^a   Bishop, J F ^a   Clarke, S J ^a  

^a SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; ERYTHROMYCIN LACTOBIONATE;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREATH TESTS; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASMS; PROTEIN BINDING;

EID: 0033812260     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
2. Clinical pharmacokinetics and dose optimisation of carboplatin
3. Noninvasive tests of CYP3A enzymes
4. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
5. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
6. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
7. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine
8. The erythromycin breath test predicts the clearance of midazolam
9. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil
10. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P450 3A
11. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio
12. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
13. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients
14. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients
15. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients
16. The erythromycin breath test as a predictor of cyclosporine blood levels
17. Erythromycin breath test predicts pharmacokinetics and clinical toxicity of docetaxel
18. In vitro and in vivo drug interactions involving human CYP3A
19. Binding of erythromycin base to human plasma proteins
20. Effects of cancer and its treatments on plasma concentration of α 1-acid glycoprotein and propranolol binding
21. Altered plasma drug binding in cancer: Role of α 1-acid glycoprotein and albumin
22. Nonlinear regression using spreadsheets
23. Intersubject and dose-related variability after intravenous administration of erythromycin
24. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity